11 research outputs found
Izotretinoina doustna w leczeniu r贸偶nych odmian klinicznych tr膮dziku pospolitego
Retinoidy to grupa syntetycznych i naturalnych substancji posiadaj膮cych aktywno艣膰
witaminy A. Isotretinoina, acytretina i etretinat r贸偶ni膮 si臋 pod wzgl臋dem farmakokinetyki,
toksyczno艣ci, jak i zastosowania klinicznego. Izotretinoina doustna od oko艂o 30 lat
pozostaje metod膮 referencyjn膮 w leczeniu objaw贸w tr膮dziku pospolitego. Daje szybkie
i d艂ugoterminowe korzy艣ci kliniczne, wp艂ywaj膮c na wszystkie najwa偶niejsze elementy
patogenetyczne tr膮dziku. Powoduje zmniejszenie wydzielania 艂oju, obni偶a liczb臋 Propionibacterium
acnes na sk贸rze, zmieniaj膮c miejscowe 艣rodowisko rozwoju bakterii
i hamuje nap艂yw kom贸rek zapalnych. Wykazuje r贸wnie偶 dzia艂anie przeciwzask贸rnikowe,
normalizuj膮c procesy rogowacenia wewn膮trzprzewodowego.
Nelson i wsp. udowodnili, i偶 izotretinoina hamuje cykl 偶yciowy kom贸rki w fazie G1/S
i indukuje apoptoz臋 w sebocytach typu SEB-1, przyczyniaj膮c si臋 do zmniejszenia wydzielania
艂oju oraz do ust臋powania objaw贸w tr膮dziku. Ostatnio opisano r贸wnie偶 patogenn膮
rol臋 P. acnes, metaloproteinaz macierzy pozakom贸rkowej (MMP, matrix metalloproteinases)
i receptor贸w Toll Like (TLRs) w fazie zapalnej tr膮dziku. Papakonstantinou
i wsp. udowodnili natomiast, i偶 doustna izotretinoina prowadzi do redukcji MMP-9
i MMP-13, dzi臋ki czemu mo偶e przyczynia膰 si臋 do poprawy zmian tr膮dzikowych i hamowa膰
bliznowacenie.
Doustna izotretinoina jest leczeniem z wyboru w ci臋偶kich postaciach tr膮dziku (posta膰
guzkowo-torbielowata, tr膮dzik ropowiczy, tr膮dzik skupiony, tr膮dzik piorunuj膮cy). Aktualne
rozszerzone wskazania zalecaj膮 stosowanie leku tak偶e w postaciach 艣rednioci臋偶kich,
niereaguj膮cych na terapi臋 konwencjonaln膮 lub cechuj膮cych si臋 nawrotami po prawid艂owo
przeprowadzonym leczeniu konwencjonalnym, w postaciach z nasilonym 艂ojotokiem
lub wykazuj膮cych tendencj臋 do bliznowacenia. Izotretinoina jest stosowana r贸wnie偶
w leczeniu innych dermatoz, m.in. tr膮dziku r贸偶owatego lub 艂uszczycy.
Dawka dzienna doustnej izotretinoiny w leczeniu tr膮dziku waha si臋 w przedziale
0,5-1,0 mg/kg/24 godz. Za optymaln膮 dawk臋 kumulacyjn膮, zapewniaj膮c膮 d艂ugotrwa艂e korzystne
efekty, uznaje si臋 120-150 mg/kg. D艂ugoterminow膮 skuteczno艣膰 wylecze艅 ocenia
si臋 na 70-89%.Czynniki zwi臋kszaj膮ce ryzyko nawrotu to: nasilony 艂ojotok i du偶a liczba zmian zapalnych pod koniec leczenia, zmiany pojawiaj膮ce si臋 przed okresem dojrzewania,
wyst臋powanie zmian na tu艂owiu oraz obci膮偶ony wywiad rodzinny w kierunku tr膮dziku.
W trakcie leczenia izotretinoin膮 mog膮 wyst膮pi膰 miejscowe dzia艂ania niepo偶膮dane,
odchylenia w badaniach laboratoryjnych i dolegliwo艣ci ze strony r贸偶nych narz膮d贸w. Zazwyczaj
maj膮 one charakter przej艣ciowy i ust臋puj膮 po zmniejszeniu dawki lub zako艅czeniu
kuracji. Najcz臋艣ciej spotykanymi dzia艂aniami niepo偶膮danymi s膮 objawy sk贸rno-艣luz贸wkowe
(zapalenie czerwieni wargowej, zapalenie spoj贸wek, krwawienia z nosa). Do
cz臋sto zg艂aszanych przez pacjent贸w objaw贸w og贸lnych nale偶膮 b贸le kostno-stawowe
i mi臋艣niowe, rzadziej b贸le g艂owy. Natomiast najcz臋stsze odchylenia laboratoryjne w trakcie
leczenia obejmuj膮 zaburzenia gospodarki lipidowej i podwy偶szenie poziomu transaminaz
w膮trobowych. Z bada艅 Zane i wsp. z 2006 roku wynika, i偶 cz臋sto艣膰 zaburze艅 lipidowych
u pacjent贸w leczonych izotretinoin膮 jest wy偶sza ni偶 we wcze艣niejszych ocenach. Jednak偶e
wi臋kszo艣膰 stwierdzanych zaburze艅 dotycz膮cych lipid贸w osoczowych i transaminaz ma
niewielkie nasilenie, przej艣ciowy i odwracalny charakter. Wyja艣nienie znaczenia klinicznego
stwierdzanych zmian wymaga prowadzenia dalszych bada艅
Presence of selected metabolic syndrome components in patients with psoriasis vulgaris
Introduction: Recent studies have suggested a strong association between psoriasis and obesity, dyslipidemia, hypertension, resistance to insulin and metabolic syndrome.
Aim : To assess the prevalence of selected metabolic syndrome components in patients with psoriasis and the effect of the abnormalities on the disease activity.
Material and methods: Two hundred and forty-six patients diagnosed with psoriasis and 75 healthy individuals as controls were included in the study. Psoriasis activity was evaluated by the Psoriasis Area and Severity Index (PASI).
Results : There was a statistically significant difference in triglyceride concentration between psoriasis patients and controls (p = 0.00001), which was not found for high-density lipoprotein (HDL) concentration. Mean values of serum glucose level in patients with psoriasis were significantly higher than in controls (p = 0.046). Further statistical analysis of the obtained results showed significantly higher systolic blood pressure in the psoriasis patients than in the controls (p = 0.0001), but there was no statistically significant difference in diastolic blood pressure between the investigated groups (p > 0.05).
Conclusions : Higher prevalence of metabolic syndrome components was observed in patients with psoriasis than in the general population
Original paper Presence of selected metabolic syndrome components in patients with psoriasis vulgaris
A b s t r a c t Introduction: Recent studies have suggested a strong association between psoriasis and obesity, dyslipidemia, hypertension, resistance to insulin and metabolic syndrome. Aim: To assess the prevalence of selected metabolic syndrome components in patients with psoriasis and the effect of the abnormalities on the disease activity. Material and methods: Two hundred and forty-six patients diagnosed with psoriasis and 75 healthy individuals as controls were included in the study. Psoriasis activity was evaluated by the Psoriasis Area and Severity Index (PASI). Results: There was a statistically significant difference in triglyceride concentration between psoriasis patients and controls (p = 0.00001), which was not found for high-density lipoprotein (HDL) concentration. Mean values of serum glucose level in patients with psoriasis were significantly higher than in controls (p = 0.046). Further statistical analysis of the obtained results showed significantly higher systolic blood pressure in the psoriasis patients than in the controls (p = 0.0001), but there was no statistically significant difference in diastolic blood pressure between the investigated groups (p > 0.05). Conclusions: Higher prevalence of metabolic syndrome components was observed in patients with psoriasis than in the general population
The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci.
To confirm the association of previously discovered psoriasis (Ps) risk loci with the disease in a Polish population and to create predictive models based on the combination of these single nucleotide polymorphisms (SNPs).Thirty-eight SNPs were genotyped in 480 Ps patients and 490 controls. Alleles distributions were compared between patients and controls, as well as between different Ps sub-phenotypes. The genetic risk score (GRS) was calculated to assess the cumulative risk conferred by multiple loci.We confirmed associations of several loci with Ps: HLA-C, REL, IL12B, TRIM39/RPP21, POU5F1, MICA. The analysis of ROC curves showed that GRS combining 16 SNPs at least nominally (uncorrected P0.05). In order to assess the total risk conferred by GRS-N, we calculated ORs according to GRS-N quartile - the Ps OR for top vs. bottom GRS-N quartiles was 12.29 (P<1 x 10-6). The analysis of different Ps sub-phenotypes showed an association of GRS-N with age of onset and family history of Ps.We confirmed the association of Ps with several previously identified genetic risk factors in a Polish population. We found that a GRS combining 16 SNPs at least nominally associated with Ps had a significantly better discriminatory ability than HLA-C or GRS combining SNPs associated with Ps after the Bonferroni correction. In contrast, adding additional SNPs to GRS did not increase significantly the discriminative power
Association of GRS-N with psoriasis sub-phenotypes.
<p>Association of GRS-N with psoriasis sub-phenotypes.</p
Demographic and clinical characteristics of the patients.
<p>Demographic and clinical characteristics of the patients.</p
The risk of psoriasis in GRS-N quartiles relative to the first quartile.
<p>The risk of psoriasis in GRS-N quartiles relative to the first quartile.</p
Comparison of ROC curves for prediction of psoriasis with the use of different genetic risk scores (GRS).
<p>GRS-ALL- GRS combining all 38 SNPs; GRS-0.1- GRS combining 19 SNPs associated/with a trend toward association with psoriasis; GRS-N- GRS combining 16 SNPs at least nominally associated with psoriasis in our cohort; GRS-B- GRS combining 6 SNPs which remained significantly associated with psoriasis after Bonferroni correction; GRS-HLA- GRS including only rs4406273 (a proxy for <i>HLA-Cw*</i>060). AUC- area under the curve.</p
Comparison of ROC curves for prediction of psoriasis with the use of different genetic risk scores: GRS-N, GRS-HLA and GRS-N(+)HLA(-).
<p>GRS-N- GRS combining 16 SNPs at least nominally associated with psoriasis; GRS-HLA- GRS including only rs4406273 (a proxy for <i>HLA-Cw*0602</i>); GRS-N(+)HLA(-) (GRS-N without rs4406273). AUC- area under the curve.</p